International Journal of Drug Delivery Technology
Volume 14, Issue 1

Development and Validation of New Discriminative Dissolution Method for Dapagliflozin Tablets

Sandip Badadhe1, Hanumant Bhusnar2, Avinash Birajdar3, Jayadeep Yadav3*, Bhagwat Chavan4

1Abasaheb Kakade College of B Pharmacy Bodhegaon, Dist-Ahmednagar, Maharashtra, India.

2Endo India Par Formulation Mumbai, Maharashtra, India.

3Dinesh Bembade College of Pharmacy, Mahalangra, Chakur, Latur, Maharashtra, India.

4JSPM’s Jayawantrao Sawant College of Pharmacy and Research, Hadapsar, Pune, Maharashtra, India.

Received: 05th January, 2024; Revised: 29th January, 2024; Accepted: 25th February, 2024; Available Online: 25th March, 2024

ABSTRACT

In this study, we aimed to find out how well dapagliflozin worked by creating and testing a new way to dissolve the pills. We considered a great many factors, including the quantity of dissolved liquid, the liquid’s composition, and the rotational speed of the paddle. Apparatus II, or the paddle, was employed to get the perfect in-vitro breakdown profile. The dissolving media consisted of 900 mL of phosphate buffer with a pH of 6.8, and the machine was spun at a speed of 50 revolutions per minute. For the purpose of assessing the drug release method’s properties, high-performance liquid chromatography (HPLC) was used. Regarding the dissolving procedure, which was found to be in compliance with regulations, all applicable laws were followed, including those of the Food and Drug Administration (FDA). Extensive evaluation of several attributes, including precision, sensitivity, accuracy, and stability, led to the conclusion that the outcomes were satisfactory. We examined the patterns of breakdown for many entities using a range of methodologies, including model-dependent methodology, model-independent methodology, and analysis of variance (ANOVA). According to the results, there was a great deal of overlap between the two things. Dapagliflozin tablet production and quality control could benefit from the melting test that was given and shown. This is because it can distinguish among the examined commodities according to their unique release characteristics.

Keywords: Dapagliflozin, Dissimilarity factor, Discriminative dissolution, Similarity factor. International Journal of Drug Delivery Technology (2024); DOI: 10.25258/ijddt.14.1.58

How to cite this article: Badadhe S, Bhusnar H, Birajdar A, Yadav J, Chavan B. Development and Validation of New Discriminative Dissolution Method for Dapagliflozin Tablets. International Journal of Drug Delivery Technology. 2024;14(1):396-404.

REFERENCES

  1. Raju V, Murthy KV. Development and validation of new discriminative dissolution method for carvedilol tablets. Indian journal of pharmaceutical sciences. 2011 Sep;73(5):527.
  2. de Meira RZ, Maciel AB, Murakami FS, de Oliveira PR, Bernardi In-vitro dissolution profile of dapagliflozin: Development, method validation, and analysis of commercial tablets. International journal of analytical chemistry. 2017 Jul 31;2017.
  3. Pund S, Dhande M, Jayatpal S, Tupe A, Deore S, Tare Scale-up and postapproval changes (SUPAC) guidelines for industry: A comprehensive review. Multidisciplinary Reviews. 2024 Jan 18;7(4):2024071.
  4. Kestur U, Patel A, Badawy S, Mathias N, Zhang L. Strategies for managing solid form transformation risk in drug product. Journal of Pharmaceutical 2023 Apr 1;112(4):909-21.
  5. Abdulwahab S, Ali EE, Hassan WS, Azab Mathematically assisted UV-spectrophotometry as a greener alternative to HPLC-UV for quality control analysis of free-drug combinations. Microchemical Journal. 2021 Nov 1;170:106638.
  6. Charoo NA, Abdallah DB, Bakheit AA, Haque KU, Hassan HA, Abrahamsson B, Cristofoletti R, Langguth P, Mehta M, Parr A, Polli Biowaiver monograph for immediate-release solid oral dosage forms: sitagliptin phosphate monohydrate. Journal of pharmaceutical sciences. 2022 Jan 1;111(1):2-13.
  7. Haque SM, Umar Y, Al-Batty S, Sarief A, Abu-Judeh A, Al-Awwad H, Rahman Charge transfer based green spectrophotometric method to determine remoglif lozin etabonate applying response surface methodology supported with computational studies in pharmaceutical formulations. Sustainable Chemistry and Pharmacy. 2023 Oct 1;35:101193.
  8. Blundell R, Butterworth P, Charlier A, Daurio D, Degenhardt M, Harris D, Hancock B, Johnston M, Kasina R, Kaye J, Kelly The role of titanium dioxide (E171) and the requirements for replacement materials in oral solid dosage forms: An IQ Consortium Working Group Review. Journal of Pharmaceutical Sciences. 2022 Nov 1;111(11):2943-54.
  9. Nagpal K, Singh SK, Mishra DN. Patent innovations in fast dissolving/disintegrating dosage forms. Current Advances in Drug Delivery Through Fast Dissolving/Disintegrating Dosage Forms. 2017 May 11:119.
  10. World Health Organization. WHO Drug Information 2016, vol. 30, 1 [full issue]. WHO Drug Information. 2016;30(1):1-92.
  11. Gondokesumo ME, Putra GS, Suhud F, Sulistyowaty In-silico studies and synthesis of 1, 3-benzoxazine derivatives as antimalarial agent through PfATP4 receptor inhibition. International Jurnal Of Pharmaceutical Research. 2021;12(2).
  12. Moinova HR, LaFramboise T, Lutterbaugh JD, Chandar AK, Dumot J, Faulx A, Brock W, De la Cruz Cabrera O, Guda K, Barnholtz-Sloan JS, Iyer PG. Identifying DNA methylation biomarkers for non-endoscopic detection of Barrett’s Science translational medicine. 2018 Jan 17;10(424):eaao5848.
  13. Dalal D, Kant R, Attri K, Sharma K, Dhanawat Spectrophotometric Absorption Correction Methods for the Estimation of Fixed-Dose Combinations of Dapagliflozin and Metformin Hydrochloride. Ind. J. Pharm. Edu. Res. 2024;58(1):291-6.
  14. Prajapati P, Rana B, Pulusu VS, Shah S. Simultaneous Chromatographic Estimation of Vildagliptin and Dapagliflozin Using Hybrid Principles of White Analytical Chemistry and Analytical Quality by Design. Journal of AOAC International. 2024 Jan 1;107(1):212-22.
  15. Shoaib A, Shahid S, Mansoor S, Javed M, Iqbal S, Mahmood S, Bahadur A, Jaber F, Alshalwi M. Tailoring of an anti- diabetic drug empagliflozin onto zinc oxide nanoparticles: characterization and in-vitro evaluation of anti-hyperglycemic potential. Scientific Reports. 2024 Jan 30;14(1):2499.
  16. Kang SJ, Kim JE. Development of clinically optimized sitagliptin and dapagliflozin complex Tablets: Pre-Formulation, Formulation, and Human Bioequivalence Pharmaceutics. 2023 Apr 14;15(4):1246.
  17. Shin JH, Kim Development and Validation of Simultaneous Quantitative Dissolution Analysis for the Two Active Pharmaceutical Ingredients in Dapagliflozin Propanediol Monohydrate-sitagliptin Phosphate Monohydrate Multi- layered Tablets. Current Pharmaceutical Analysis. 2023 Dec 1;19(10):776-85.
  18. Kartikey A, Gupta A, Gupta Formulation and Evaluation of Bilayer Tablet of Dapagliflozin and Vildagliptin. Journal of Population Therapeutics and Clinical Pharmacology. 2023 Jan 14;30(1):714-23.
  19. Chaudhari U, Sahu JK, Dande PR. Analytical Method Development, Validation and Forced Degradation Study of Dapagliflozin by RP-HPLC. Drug Metabolism and Bioanalysis Letters Formerly: Drug Metabolism Letters. 2023 Jul 1;16(2):140-52.
  20. Desai S, Maradia RB, Suhagia BN. A Comprehensive and Critical Review on Analytical and Bioanalytical methods for Metformin Hydrochloride, Dapagliflozin, and Saxagliptin. Current Pharmaceutical Analysis. 2023 Jan 1;19(1):20-50.
  21. Jadhav SA, Bhilare NA, Chandanshive B, Dyade GK, Lunkad AS. Sustainable Green Analytical Chemistry: Spectrophotometric Method Development of Dapagliflozin and Omeprazole by Using Eco-friendly Current Research in Pharmaceutical Sciences. 2023:179-87.
  22. Kim CH, Lee SH, Kim Development of a novel dapagliflozin orally disintegrating tablets. Yakhak Hoeji. 2020 Aug 31;64(4):334-42.
  23. Algahtani MS, Mohammed AA, Ahmad J, Abdullah MM, Saleh 3D printing of dapagliflozin containing self-nanoemulsifying tablets: Formulation design and in-vitro characterization. Pharmaceutics. 2021 Jun 30;13(7):993.